Schein Pharmaceutical announces exclusive distribution agreement with Invamed for Captopril and Nadolol; Move Strengthens Schein's Cardiovascular Portfolio.FLORHAM PARK, N.J.--(HealthWire)--Feb. 14, 1996--Schein Pharmaceutical, Inc. today announced that it has entered into an exclusive agreement with Invamed, Inc. for the distribution of multisource versions of Bristol-Myers Squibb's cardiovascular compounds Capoten (captopril captopril /cap·to·pril/ (kap´to-pril) an angiotensin-converting enzyme inhibitor used in the treatment of hypertension, congestive heart failure, and post–myocardial infarction left ventricular dysfunction. ) and Corgard (nadolol). Under the agreement, Invamed will manufacture the products, which Schein will market and distribute in the United States United States, officially United States of America, republic (2005 est. pop. 295,734,000), 3,539,227 sq mi (9,166,598 sq km), North America. The United States is the world's third largest country in population and the fourth largest country in area. . "We are pleased to be associated with Invamed in marketing these two important products, particularly in light of Capoten's patent expiration," said Martin Sperber, Chairman and Chief Executive Officer of Schein Pharmaceutical. "The combination of Invamed's world class product development and manufacturing infrastructure and Schein's established marketing, sales and distribution strengths will prove to be a formidable presence in today's competitive marketplace." Captopril, an ACE (angiotensin angiotensin /an·gio·ten·sin/ (-ten´sin) a decapeptide hormone (a. I) formed from the plasma glycoprotein angiotensinogen by renin secreted by the juxtaglomerular apparatus. I-converting enzyme) inhibitor, and nadolol, a nonselective beta-adrenergic receptor beta-adrenergic receptor n. Any of various cell membrane receptors that can bind with epinephrine and related substances that activate or block the actions of cells containing such receptors. blocking agent blocking agent n. A drug that blocks transmission of nerve impulses at an autonomic receptor site, autonomic synapse, or neuromuscular junction. ("beta blocker Beta blocker A drug that can be used to reduce blood pressure. Mentioned in: Mitral Valve Stenosis beta blocker Beta-adrenergic blocking agent Pharmacology Any of a class of agents that blocks β1 "), are the latest additions to Schein's stable of cardiovascular products. "Our joining forces with Schein will further establish Invamed's presence in the United States multisource marketplace," said Ashok Patel Ashok Kurjibhai Patel pronunciation (born 6 March 1957 in Bhavnagar, India) is a former Indian cricketer. , President of Invamed. "We look forward to further agreements of this kind." Shein Pharmaceutical, Inc. is one of the leading multisource companies in the U.S., employing over 1,800 people at seven facilities; Florham Park, NJ; Carmel, NY; Brewster, NY; Danbury, CT; Phoenix; Humacao, PR; and Cherry Hill, NJ. Schein manufactures over 400 pharmaceutical products in nearly every therapeutic category. The company maintains modern manufacturing facilities, invests significantly in product development, and focuses on controlling health care costs through state-of-the-art production, distribution and competitive pricing of quality merchandise. Invamed, Inc., based in Dayton, NJ, develops and manufactures multisource drugs. CONTACT: Schein Pharmaceutical, Florham Park Suzanne Soderberg 201/593-5565 201/593-5820 (fax) or Invamed, Inc., Dayton Yashvant Patel 201/575-3303 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion